{"filing":{"accession_number":"0001493152-26-040080","cik":"0001716947","ticker":"ENSCW","company_name":"Ensysce Biosciences, Inc.","form":"8-K","filing_date":"2026-08-25","report_date":"2026-08-25","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226040080/form8-k.htm"},"events":[{"id":29554,"run_id":27064,"accession_number":"0001493152-26-040080","anchor_item_number":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.85,"summary":"The filing discloses multiple delisting risks under Item 8.01. Nasdaq notified the Company on August 25, 2026 that it must evidence compliance with the $2.5 million stockholders' equity requirement in its next periodic report or face delisting, and separately granted an additional 180-day extension (until February 22, 2027) to regain compliance with the Minimum Price Listing Requirement after the stock closed below $1.00 for 30 consecutive business days. Additionally, the Cy Biopharma acquisition triggers a Change of Control requiring the post-transaction company to satisfy Nasdaq's initial listing criteria, with failure to do so resulting in trading suspension. These are material threats to the Company's continued listing status.","company_name":"Ensysce Biosciences, Inc.","ticker":"ENSCW","filing_date":"2026-08-25","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":31872,"accession_number":"0001493152-26-040080","item_number":null,"item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.85,"reasoning":"The filing discloses multiple delisting risks under Item 8.01. Nasdaq notified the Company on August 25, 2026 that it must evidence compliance with the $2.5 million stockholders' equity requirement in its next periodic report or face delisting, and separately granted an additional 180-day extension (until February 22, 2027) to regain compliance with the Minimum Price Listing Requirement after the stock closed below $1.00 for 30 consecutive business days. Additionally, the Cy Biopharma acquisition triggers a Change of Control requiring the post-transaction company to satisfy Nasdaq's initial listing criteria, with failure to do so resulting in trading suspension. These are material threats to the Company's continued listing status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T21:13:37.048360+00:00","company_name":"Ensysce Biosciences, Inc.","ticker":"ENSCW","filing_date":"2026-08-25"}]}